Paolo E. Coppola

Bologna, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia.

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia.

Journal: Blood advances
Published: May 24, 2023

Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series.

Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series.

Journal: Tumori
Published: April 20, 2022

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience.

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience.

Journal: Journal of cancer research and clinical oncology
Published: January 17, 2022

Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.

Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.

Journal: Leukemia & lymphoma
Published: August 04, 2021

The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience.

The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience.

Journal: American journal of hematology
Published: May 05, 2021

Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients.

Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients.

Journal: Microorganisms
Published: November 12, 2020

Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience.

Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience.

Journal: Hematological oncology
Published: July 06, 2020

Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients.

Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients.

Journal: Annals of hematology
Published: June 10, 2020

Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.

Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.

Journal: Hematological oncology
Published: May 04, 2020

Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.

Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.

Journal: Cancer medicine
Published: March 30, 2020
Showing 1-10 of 10

Last Updated: 09/26/2026